Neutralizing activity and 3-month durability of tixagevimab and cilgavimab prophylaxis against Omicron sublineages in transplant recipients

[1]  Peng Wang,et al.  Imprinted SARS-CoV-2 humoral immunity induces convergent Omicron RBD evolution , 2022, bioRxiv.

[2]  A. Sigal,et al.  Omicron BA.4/BA.5 escape neutralizing immunity elicited by BA.1 infection , 2022, Nature Communications.

[3]  L. Braun-Parvez,et al.  A rapid decline in the anti–receptor-binding domain of the SARS-CoV-2 spike protein IgG titer in kidney transplant recipients after tixagevimab–cilgavimab administration , 2022, Kidney International.

[4]  H. van Bakel,et al.  Efficacy of Antibodies and Antiviral Drugs against Omicron BA.2.12.1, BA.4, and BA.5 Subvariants , 2022, The New England journal of medicine.

[5]  Qian Wang,et al.  Antibody evasion by SARS-CoV-2 Omicron subvariants BA.2.12.1, BA.4 and BA.5 , 2022, Nature.

[6]  P. Merville,et al.  COVID-19 morbidity decreases with tixagevimab–cilgavimab preexposure prophylaxis in kidney transplant recipient nonresponders or low-vaccine responders , 2022, Kidney International.

[7]  L. Braun-Parvez,et al.  Breakthrough COVID-19 cases despite prophylaxis with 150 mg of tixagevimab and 150 mg of cilgavimab in kidney transplant recipients , 2022, American Journal of Transplantation.

[8]  L. Riella,et al.  Tixagevimab/cilgavimab pre-exposure prophylaxis is associated with lower breakthrough infection risk in vaccinated solid organ transplant recipients during the omicron wave , 2022, American Journal of Transplantation.

[9]  M. Pangalos,et al.  Intramuscular AZD7442 (Tixagevimab–Cilgavimab) for Prevention of Covid-19 , 2022, The New England journal of medicine.

[10]  P. Maes,et al.  Serum neutralization of SARS-CoV-2 Omicron sublineages BA.1 and BA.2 in patients receiving monoclonal antibodies , 2022, Nature Medicine.

[11]  J. Blankson,et al.  A third dose of SARS-CoV-2 vaccine increases neutralizing antibodies against variants of concern in solid organ transplant recipients , 2021, American Journal of Transplantation.

[12]  O. Schwartz,et al.  A fourth dose of the mRNA-1273 SARS-CoV-2 vaccine improves serum neutralization against the Delta variant in kidney transplant recipients , 2021, Kidney International.

[13]  Jordan J. Clark,et al.  Activity of convalescent and vaccine serum against SARS-CoV-2 Omicron , 2021, Nature.

[14]  Qulu Zheng,et al.  Association Between Immune Dysfunction and COVID-19 Breakthrough Infection After SARS-CoV-2 Vaccination in the US. , 2021, JAMA internal medicine.

[15]  J. Izopet,et al.  Assessment of 4 Doses of SARS-CoV-2 Messenger RNA–Based Vaccine in Recipients of a Solid Organ Transplant , 2021, JAMA network open.

[16]  J. Blankson,et al.  A third dose of SARS-CoV-2 vaccine increases neutralizing antibodies against variants of concern in solid organ transplant recipients , 2021, American Journal of Transplantation.

[17]  P. Shah,et al.  Risk of Breakthrough SARS-CoV-2 Infections in Adult Transplant Recipients , 2021, Transplantation.

[18]  D. Segev,et al.  Safety and Immunogenicity of a Third Dose of SARS-CoV-2 Vaccine in Solid Organ Transplant Recipients: A Case Series , 2021, Annals of Internal Medicine.

[19]  D. Segev,et al.  Immunogenicity of a Single Dose of SARS-CoV-2 Messenger RNA Vaccine in Solid Organ Transplant Recipients. , 2021, JAMA.

[20]  D. Solís.  US Food and Drug Administration , 2010 .